secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001104659-26-018837
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC
--------------------------------------------------------------------------------

- Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.
- Gross margin improved to ~50% in Q4; cash $303M funds operations into Q3 2027.
- FDA Fast Track granted for lifileucel in second-line advanced nonsquamous NSCLC; potential launch 2H27.
- Real-world Amtagvi ORR ~44% at Tandem Meetings; 52% in patients with ≤2 prior lines.
- Sarcoma early data: 50% ORR (6 evaluable); registrational trial to start Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/0001104659-26-018837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/tm266992d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer